ArticlebioRxiv : the preprint server for biology2026
Multi-modality Graph Representation Learning for Malignant Cell Identification from scRNA-seq using DeepMalignant.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Distinguishing malignant from normal cells in single-cell RNA sequencing data remains a critical yet challenging task in cancer genomics. Existing methods often suffer from poor precision, limited generalizability across cancer types, and reduced robustness across different sequencing platforms. We developed DeepMalignant, an unsupervised multimodal graph attention autoencoder for malignant cell identification that jointly integrates gene expression and copy number alteration (CNA) information. We applied DeepMalignant to five datasets covering 26 samples and four cancer types (breast, colorectal, pancreatic, and ovarian cancers), generated by three platforms (10x Genomics, inDrop, and Drop-seq) for benchmarking and compared it with existing state-of-the-art methods including scMalignantFinder, PreCanCell, CopyKAT, ikarus, and Cancer-Finder. DeepMalignant achieved the best overall balance of precision and recall and consistently outperformed the existing methods that used either gene expression or CNA in F1 scores. Ablation studies showed that both CNA-based edge weighting and graph attention aggregation contribute independently to performance, and attribution analysis further indicated that the learned embeddings capture biologically meaningful malignant programs. We further applied DeepMalignant to two ductal carcinoma in situ (DCIS) samples, DCIS2 and DCIS1, that have matched spatial transcriptomics and scRNA-seq data. DeepMalignant identified tumor-enriched regions that were highly consistent with the matched histological image. The downstream cell-cell communications analysis revealed that fibroblast-derived C3 and MIF both directed signaling more toward normal epithelial cells than tumor epithelial cells, demonstrating that accurate tumor-normal cell classification by DeepMalignant enables biologically meaningful interrogation of the tumor microenvironment and revealing how stromal cells differentially communicate with malignant versus normal epithelial populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.